Mostrar el registro sencillo del ítem
dc.contributor.author | Accinelli Tanaka, Roberto Alfonso | |
dc.contributor.author | Ynga-Meléndez, G.J. | |
dc.contributor.author | Leon-Abarca, Juan Alonso | |
dc.contributor.author | Lopez Oropeza, Lidia Marianella | |
dc.contributor.author | Madrid-Cisneros, J.C. | |
dc.contributor.author | Mendoza-Saldaña, J.D. | |
dc.date.accessioned | 2021-12-12T20:24:54Z | |
dc.date.available | 2021-12-12T20:24:54Z | |
dc.date.issued | 2021 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12866/10201 | |
dc.description.abstract | Background: Currently, there is no formally accepted pharmacological treatment for COVID-19. Materials and methods: We included COVID-19 outpatients of a Peruvian primary care center from Lima, Peru, who were treated between April 30 - September 30, 2020, with hydroxychloroquine and azithromycin. Logistic regression was applied to determine factors associated with case-fatality rate. Results: A total of 1265 COVID-19 patients with an average age of 44.5 years were studied. Women represented 50.1% of patients, with an overall 5.9 symptom days, SpO2 97%, temperature of 37.3 °C, 41% with at least one comorbidity and 96.1% one symptom or sign. No patient treated within the first 72 h of illness died. The factors associated with higher case fatality rate were age (OR = 1.06; 95% CI 1.01–1.11, p = 0.021), SpO2 (OR = 0.87; 95% CI 0.79–0.96, p = 0.005) and treatment onset (OR = 1.16; 95% CI 1.06–1.27, p = 0.002), being the latter the only associated in the multivariate analysis (OR = 1.18; 95% CI 1.05–1.32, p = 0.005). 0.6% of our patients died. Conclusions: The case fatality rate in COVID-19 outpatients treated with hydroxychloroquine/azithromycin was associated with the number of days of illness on which treatment was started | en_US |
dc.language.iso | eng | |
dc.publisher | Elsevier | |
dc.relation.ispartofseries | Travel Medicine and Infectious Disease | |
dc.rights | info:eu-repo/semantics/restrictedAccess | |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es | |
dc.subject | abdominal pain | en_US |
dc.subject | adult | en_US |
dc.subject | aged | en_US |
dc.subject | ageusia | en_US |
dc.subject | anosmia | en_US |
dc.subject | arthralgia | en_US |
dc.subject | Article | en_US |
dc.subject | azithromycin | en_US |
dc.subject | Azithromycin | en_US |
dc.subject | backache | en_US |
dc.subject | body temperature | en_US |
dc.subject | case fatality rate | en_US |
dc.subject | child | en_US |
dc.subject | chill | en_US |
dc.subject | clinical feature | en_US |
dc.subject | comorbidity | en_US |
dc.subject | coronavirus disease 2019 | en_US |
dc.subject | coughing | en_US |
dc.subject | COVID-19 | en_US |
dc.subject | decreased appetite | en_US |
dc.subject | diarrhea | en_US |
dc.subject | disease duration | en_US |
dc.subject | dizziness | en_US |
dc.subject | drug withdrawal | en_US |
dc.subject | dyspnea | en_US |
dc.subject | eye redness | en_US |
dc.subject | female | en_US |
dc.subject | fever | en_US |
dc.subject | headache | en_US |
dc.subject | human | en_US |
dc.subject | hydroxychloroquine | en_US |
dc.subject | Hydroxychloroquine | en_US |
dc.subject | infant | en_US |
dc.subject | irritability | en_US |
dc.subject | major clinical study | en_US |
dc.subject | male | en_US |
dc.subject | Mortality | en_US |
dc.subject | myalgia | en_US |
dc.subject | nausea | en_US |
dc.subject | newborn | en_US |
dc.subject | nose obstruction | en_US |
dc.subject | outpatient care | en_US |
dc.subject | pain | en_US |
dc.subject | Peru | en_US |
dc.subject | Peruvian | en_US |
dc.subject | primary medical care | en_US |
dc.subject | rash | en_US |
dc.subject | SARS-CoV-2 | en_US |
dc.subject | sore throat | en_US |
dc.subject | thorax pain | en_US |
dc.subject | time to treatment | en_US |
dc.subject | Time-to-Treatment | en_US |
dc.subject | unspecified side effect | en_US |
dc.subject | very elderly | en_US |
dc.subject | vomiting | en_US |
dc.title | Hydroxychloroquine / azithromycin in COVID-19: The association between time to treatment and case fatality rate | en_US |
dc.type | info:eu-repo/semantics/article | |
dc.identifier.doi | https://doi.org/10.1016/j.tmaid.2021.102163 | |
dc.relation.issn | 1873-0442 |
Ficheros | Tamaño | Formato | Ver |
---|---|---|---|
No hay ficheros asociados a este ítem. |